Insilico Medicine to present innovation analytics at SAPHEX 2018


Credit: Insilico Medicine

Wednesday, October 31, 2018, 2018, Rockville, MD – Insilico Medicine, a Rockville-based company developing the end-to-end drug discovery pipeline utilizing the next generation artificial intelligence is pleased to announce the keynote of Iraneus Ogu the director, Africa Artificial Intelligence and Blockchain for Healthcare Initiative at Insilico Medicine, Inc at SAPHEX 2018.

Taking place 1st – 2nd November 2018 at the Gallagher Convention Centre in Midrand, South Africa, SAPHEX will be bringing together industry leaders, non-governmental organizations, key import and export authorities, local associations to facilitate business in Africa's pharmaceutical industry.

"We are very happy to present our work at the at SAPHEX 2018, which brings together many African experts from pharmaceutical and healthcare industry. The topic of Artificial Intelligence for pharma R&D is rapidly gaining popularity and we are happy to be at the leading edge of research and one of the innovation drivers in this area", said Alex Zhavoronkov, PhD, the Founder and CEO of Insilico Medicine, Inc.

Keynote by Iraneus Ogu will address the theme innovation analytics. According to Iraneus, "the developments in the pharmaceutical sector have the potential to not only transform healthcare and help us address most tropical healthcare challenges but could help transform the whole economic landscape in Africa. Advances in tech such a machine learning could for instance help accelerate progress in drug discovery while also easing the resource constraints preventing many institutions and individuals in Africa from making original and transformative contributions to healthcare systems in Africa and beyond."

"The knowledge we share and the projects we are working to establish around Africa would not only help advance healthcare developments and help people maintain health but would help transform every other aspect of the social and economic development of the people", said Iraneus Ogu.


Insilico Medicine is regularly publishing research papers in peer-reviewed journals. The company was first to apply the generative adversarial networks (GANs) to the generation of the new molecular structures with the specified parameters and published a seminal peer-reviewed paper submitted in June 2016. The concept was further extended and augmented with advanced memory and reinforcement learning. One of the latest papers published in the Journals of Gerontology demonstrated the application of the deep neural networks to assessing the biological age of the patients. The latest special issue in Molecular Pharmaceutics featured several research papers by Insilico Medicine.

For further information, images or interviews, please contact:

Contact: Klug Gehilfer

[email protected]


Official website of the conference:

About Insilico Medicine, Inc

Insilico Medicine is an artificial intelligence company headquartered in Rockville, with R&D and management resources in Belgium, Russia, UK, Taiwan, and Korea sourced through hackathons and competitions. The company and its scientists are dedicated to extending human productive longevity and transforming every step of the drug discovery and drug development process through excellence in biomarker discovery, drug development, digital medicine, and aging research.

Insilico pioneered the applications of the generative adversarial networks (GANs) and reinforcement learning for generation of novel molecular structures for the diseases with a known target and with no known targets. In addition to working collaborations with the large pharmaceutical companies, the company is pursuing internal drug discovery programs in cancer, dermatological diseases, fibrosis, Parkinson's Disease, Alzheimer's Disease, ALS, diabetes, sarcopenia, and aging. Through a partnership with, the company launched a range of nutraceutical products compounded using the advanced bioinformatics techniques and deep learning approaches. It also provides a range of consumer-facing applications including Young.AI.

In 2017, NVIDIA selected Insilico Medicine as one of the Top 5 AI companies in its potential for social impact. In 2018, the company was named one of the global top 100 AI companies by CB Insights. In 2018 it received the Frost & Sullivan 2018 North American Artificial Intelligence for Aging Research and Drug Development Award accompanied with the industry brief. Brief company video:

Media Contact

Qingsong Zhu
[email protected]